Petrocheilou Argyri, Moudaki Aggeliki, Kaditis Athanasios G
Cystic Fibrosis Department, Agia Sofia Children's Hospital, 11527 Athens, Greece.
Division of Pediatric Pulmonology, First Department of Pediatrics, University of Athens School of Medicine and Agia Sophia Children's Hospital, 11527 Athens, Greece.
Children (Basel). 2022 Dec 2;9(12):1898. doi: 10.3390/children9121898.
Inflammation and infection play an important role in the pathophysiology of cystic fibrosis, and they are significant causes of morbidity and mortality in CF. The presence of thick mucus in the CF airways predisposes to local hypoxia and promotes infection and inflammation. A vicious cycle of airway obstruction, inflammation, and infection is of critical importance for the progression of the disease, and new data elucidate the different factors that influence it. Recent research has been focused on improving infection and inflammation in addition to correcting the basic gene defect. This review aims to summarize important advances in infection and inflammation as well as the effect of new treatments modulating the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. New approaches to target infection and inflammation are being studied, including gallium, nitric oxide, and phage therapy for infection, along with retinoids and neutrophil elastase inhibitors for inflammation.
炎症和感染在囊性纤维化的病理生理学中起着重要作用,它们是囊性纤维化患者发病和死亡的重要原因。囊性纤维化气道中浓稠黏液的存在易导致局部缺氧,并促进感染和炎症。气道阻塞、炎症和感染的恶性循环对疾病进展至关重要,新数据阐明了影响该循环的不同因素。除了纠正基本基因缺陷外,近期研究一直聚焦于改善感染和炎症。本综述旨在总结感染和炎症方面的重要进展以及调节囊性纤维化跨膜传导调节因子(CFTR)蛋白的新疗法的效果。针对感染和炎症的新方法正在研究中,包括用于感染的镓、一氧化氮和噬菌体疗法,以及用于炎症的类维生素A和中性粒细胞弹性蛋白酶抑制剂。